Form 4 for LCTX Lineage Cell Therapeutics, Inc.
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-11 · accession 0001493152-23-004898 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-14 | 2023-02-11 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | — | +31.2K | 139.1K | +29% | — |
| D | 2023-02-14 | 2023-02-11 | LCTX | Culley Brian M | Pres, CEO, Dir | F - Tax | $1.35 | -12.7K | 126.4K | -9% | -$17.2K |
| D | 2023-02-14 | 2023-02-11 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | $0.00 | -31.2K | 93.7K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares, no par value | 2023-02-11 | M | A | 31,249 | — | 139,143 | D | — | — | (F1) Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. (F2) Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. |
| 2 | Common | Common Shares, no par value | 2023-02-11 | F | D | 12,744 | $1.35 | 126,399 | D | — | — | (F3) Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. (F2) Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. |
| 3 | Derivative | Restricted Stock Units | 2023-02-11 | M | D | 31,249 | $0.00 | 93,748 | D | $0.00 · — to — | 31,249 Common Shares | (F4) The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. |